Flamingo Therapeutics appoints new board member and more digital health hires

RNA-focused digital therapeutics company Flamingo Therapeutics appointed Dr. Ezra Cohen to its board of directors. The company specializes in RNA therapies for oncology and is supported by various investors. Dr. Cohen has a background in developing pharmaceuticals, particularly for head and neck cancers. He is optimistic about Flamingo’s potential to improve treatment options in oncology. On the other hand, life sciences software company Synthace named Willem Baralt as its new chairman of the board. Baralt sees Synthace’s digital experimentation platform as revolutionary in the field by enabling scientists to conduct experiments that were previously impossible, leading to significant advancements in R&D.

Source link

error: Content is protected !!